SynCore Biotechnology Co., Ltd. (4192) AI Stock Analysis

SynCore Biotechnology Co., Ltd.

(TPEx:4192)

Select Model

Rating:46Neutral

Price Target:TWD 15.50▼(-5.78% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is constrained primarily by persistent unprofitability and negative cash flow, despite a strong, lightly leveraged balance sheet. Weak technical positioning and a negative P/E further reduce the score.

Positive Factors

Revenue ExpansionRevenue has more than doubled since 2020 and accelerated meaningfully in 2025, indicating greater commercial scale and improving demand for the company’s offerings. If sustained, this larger revenue base can help spread operating costs and create a path toward improved profitability over the next several quarters.

Negative Factors

Persistent Operating LossesSynCore has not yet demonstrated a sustainable profit model: operating and net losses remain substantial compared with its revenue base. Continued losses can absorb capital, limit internally funded investment, and make the company’s improved revenue and gross margin less valuable until operating expenses are brought under control.

SynCore Biotechnology Co., Ltd. (4192) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 552.09M
Dividend Yield: ―
Average Volume (3M): 14.97K
Price to Earnings (P/E): -0.0
Beta (1Y): 0.42
Revenue Growth: -1.68%
EPS Growth: -5.45%
Country: TW
Employees: 40
Sector: General
Sector Strength: 55
Industry: Biotechnology

SynCore Biotechnology Co., Ltd. Business Overview & Revenue Model

Company Description

SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes se...

SynCore Biotechnology Co., Ltd. Financial Statement Overview

Summary

Financial quality is below average: strong equity and very low debt support the balance sheet, but ongoing net losses, negative operating cash flow, negative free cash flow, and declining equity remain significant risks. The score reflects the balance sheet strength offset by weak profitability and cash generation.

Income Statement

35Negative

Balance Sheet

76Positive

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	26.24M	27.04M	23.34M	20.20M	15.86M	6.94M
Gross Profit	21.36M	21.09M	12.89M	521.00K	9.09M	2.97M
EBITDA	-32.66M	-29.62M	-35.80M	-17.73M	-146.32M	-404.13M
Net Income	-46.85M	-45.76M	-54.28M	-38.17M	-188.67M	-458.60M
Balance Sheet
Total Assets	239.78M	255.70M	317.80M	378.36M	436.65M	824.44M
Cash, Cash Equivalents and Short-Term Investments	145.80M	164.41M	212.44M	271.36M	275.81M	559.63M
Total Debt	12.53M	2.10M	7.98M	2.11M	71.76M	125.46M
Total Liabilities	20.60M	10.07M	23.11M	21.23M	187.64M	381.52M
Stockholders Equity	219.18M	245.63M	294.69M	357.14M	249.01M	442.92M
Cash Flow
Free Cash Flow	-32.65M	-38.74M	-49.70M	-83.13M	-210.65M	-231.50M
Operating Cash Flow	-32.41M	-38.33M	-49.24M	-82.37M	-209.61M	-229.86M
Investing Cash Flow	-860.00K	-252.00K	-457.00K	-778.00K	-1.03M	-1.64M
Financing Cash Flow	-9.45M	-9.63M	-9.51M	78.67M	-73.21M	245.31M

SynCore Biotechnology Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4192 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4192	46Neutral	TWD 563.91M	-0.01	―	―	-1.68%	-5.45%

* General Sector Average

Performance Comparison

TW:4192 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4192	SynCore Biotechnology Co., Ltd.	16.45	-9.05	-35.49%
TW:4117	General Biologicals Corp.	7.80	-4.65	-37.35%
TW:4170	Vectorite Biomedical, Inc.	11.00	-2.60	-19.12%
TW:4186	Taiwan Advance Bio-Pharmaceutical, Inc.	6.95	-6.05	-46.54%
TW:6549	TaiwanJ Pharmaceuticals Co., Ltd.	6.25	-1.47	-19.04%
TW:6939	TFBS Bioscience, Inc.	19.40	-4.35	-18.32%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

SynCore Biotechnology Co., Ltd. AI Stock Analysis